Verona Pharma - VRNA Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $23.00 to $27.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 84.0% from the stock's current price.
View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts.

Verona Pharma's stock was trading at $6.72 on January 1st, 2022. Since then, VRNA stock has increased by 102.2% and is now trading at $13.59.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VRNA earnings forecast.

Verona Pharma will be holding an earnings conference call on Monday, August 15th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.18.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Verona Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (0.50%), D.A. Davidson & CO. (0.07%), Renaissance Technologies LLC (0.05%) and Forefront Analytics LLC (0.05%). Insiders that own company stock include Anders Ullman, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn and Patrick John Finn.
View institutional ownership trends.

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRNA stock can currently be purchased for approximately $13.59.

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $820.40 million and generates $40 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.